Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 90

1.

Ex vivo evolution of human antibodies by CRISPR-X: from a naive B cell repertoire to affinity matured antibodies.

Devilder MC, Moyon M, Gautreau-Rolland L, Navet B, Perroteau J, Delbos F, Gesnel MC, Breathnach R, Saulquin X.

BMC Biotechnol. 2019 Feb 18;19(1):14. doi: 10.1186/s12896-019-0504-z. No abstract available.

2.

Evaluation of the effectiveness of kINPen Med plasma jet and bioactive agent therapy in a rat model of wound healing.

Breathnach R, McDonnell KA, Chebbi A, Callanan JJ, Dowling DP.

Biointerphases. 2018 Oct 16;13(5):051002. doi: 10.1116/1.5046489.

PMID:
30326703
3.

The Juxtamembrane Domain of Butyrophilin BTN3A1 Controls Phosphoantigen-Mediated Activation of Human Vγ9Vδ2 T Cells.

Peigné CM, Léger A, Gesnel MC, Konczak F, Olive D, Bonneville M, Breathnach R, Scotet E.

J Immunol. 2017 Jun 1;198(11):4228-4234. doi: 10.4049/jimmunol.1601910. Epub 2017 May 1.

4.

Antimicrobial efficacy of an innovative emulsion of medium chain triglycerides against canine and feline periodontopathogens.

Laverty G, Gilmore BF, Jones DS, Coyle L, Folan M, Breathnach R.

J Small Anim Pract. 2015 Apr;56(4):253-63. doi: 10.1111/jsap.12344. Epub 2015 Feb 28.

PMID:
25728584
5.

The intracellular B30.2 domain of butyrophilin 3A1 binds phosphoantigens to mediate activation of human Vγ9Vδ2 T cells.

Sandstrom A, Peigné CM, Léger A, Crooks JE, Konczak F, Gesnel MC, Breathnach R, Bonneville M, Scotet E, Adams EJ.

Immunity. 2014 Apr 17;40(4):490-500. doi: 10.1016/j.immuni.2014.03.003. Epub 2014 Apr 3.

6.

Key implication of CD277/butyrophilin-3 (BTN3A) in cellular stress sensing by a major human γδ T-cell subset.

Harly C, Guillaume Y, Nedellec S, Peigné CM, Mönkkönen H, Mönkkönen J, Li J, Kuball J, Adams EJ, Netzer S, Déchanet-Merville J, Léger A, Herrmann T, Breathnach R, Olive D, Bonneville M, Scotet E.

Blood. 2012 Sep 13;120(11):2269-79. doi: 10.1182/blood-2012-05-430470. Epub 2012 Jul 5.

7.

Association between skin surface pH, temperature and Staphylococcus pseudintermedius in dogs with immunomodulatory-responsive lymphocytic-plasmacytic pododermatitis.

Breathnach RM, Quinn PJ, Baker KP, McGeady T, Strobl E, Abbott Y, Jones BR.

Vet Dermatol. 2011 Aug;22(4):312-8. doi: 10.1111/j.1365-3164.2010.00946.x. Epub 2011 Mar 11.

PMID:
21395884
8.

Combined use of MS2 and PP7 coat fusions shows that TIA-1 dominates hnRNP A1 for K-SAM exon splicing control.

Gesnel MC, Del Gatto-Konczak F, Breathnach R.

J Biomed Biotechnol. 2009;2009:104853. doi: 10.1155/2009/104853. Epub 2010 Jan 14.

9.

Cutaneous infiltrates and peripheral blood immune responses in dogs with immunomodulatory-responsive lymphocytic-plasmacytic pododermatitis.

Breathnach RM, Fanning S, Mulcahy G, Bassett HF, Strobl E, Jones BR.

Vet Dermatol. 2010 Aug;21(4):383-92. doi: 10.1111/j.1365-3164.2009.00791.x. Epub 2009 Dec 14.

PMID:
20015110
10.

Canine pododermatitis and idiopathic disease.

Breathnach RM, Fanning S, Mulcahy G, Bassett HF, Jones BR.

Vet J. 2008 May;176(2):146-57. Epub 2007 Oct 4. Review.

PMID:
17919951
11.

A study of dendritic cell and MHC class II expression in dogs with immunomodulatory-responsive lymphocytic-plasmacytic pododermatitis.

Breathnach RM, Fanning S, Mulcahy G, Bassett HF, Jones BR.

Vet J. 2008 Sep;177(3):352-9. Epub 2007 Sep 4.

PMID:
17804263
12.

Cooperative binding of TIA-1 and U1 snRNP in K-SAM exon splicing activation.

Gesnel MC, Theoleyre S, Del Gatto-Konczak F, Breathnach R.

Biochem Biophys Res Commun. 2007 Jul 13;358(4):1065-70. Epub 2007 May 15.

PMID:
17512901
13.

Complex interplay of activating and inhibitory signals received by Vgamma9Vdelta2 T cells revealed by target cell beta2-microglobulin knockdown.

Trichet V, Benezech C, Dousset C, Gesnel MC, Bonneville M, Breathnach R.

J Immunol. 2006 Nov 1;177(9):6129-36.

14.
15.

The psychedelic haze of inflammation.

Breathnach R.

Vet J. 2007 Jan;173(1):14-5. Epub 2006 Mar 22. No abstract available.

PMID:
16554178
17.

Characterization of certain inflammatory variables in the peripheral blood of clinically healthy dogs.

Breathnach R, Donahy C, Jones BR, Bloomfield FJ.

Vet J. 2006 Jan;171(1):98-105.

PMID:
16427586
18.

Clinical, immunological and histopathological findings in a subpopulation of dogs with pododermatitis.

Breathnach RM, Baker KP, Quinn PJ, McGeady TA, Aherne CM, Jones BR.

Vet Dermatol. 2005 Dec;16(6):364-72.

PMID:
16359303
19.
20.

Intronic UGG repeats coordinate splicing of CD44 alternative exons v8 and v9.

Galiana-Arnoux D, Del Gatto-Konczak F, Gesnel MC, Breathnach R.

Biochem Biophys Res Commun. 2005 Oct 21;336(2):667-73.

PMID:
16137657
21.

TIA proteins are necessary but not sufficient for the tissue-specific splicing of the myosin phosphatase targeting subunit 1.

Shukla S, Dirksen WP, Joyce KM, Le Guiner-Blanvillain C, Breathnach R, Fisher SA.

J Biol Chem. 2004 Apr 2;279(14):13668-76. Epub 2004 Jan 20.

22.

Tetanus in the dog: review and a case-report of concurrent tetanus with hiatal hernia.

Acke E, Jones BR, Breathnach R, McAllister H, Mooney CT.

Ir Vet J. 2004 Oct 1;57(10):593-7. doi: 10.1186/2046-0481-57-10-593.

23.

The CD44 alternative v9 exon contains a splicing enhancer responsive to the SR proteins 9G8, ASF/SF2, and SRp20.

Galiana-Arnoux D, Lejeune F, Gesnel MC, Stevenin J, Breathnach R, Del Gatto-Konczak F.

J Biol Chem. 2003 Aug 29;278(35):32943-53. Epub 2003 Jun 24.

24.

TIA-1 or TIAR is required for DT40 cell viability.

Le Guiner C, Gesnel MC, Breathnach R.

J Biol Chem. 2003 Mar 21;278(12):10465-76. Epub 2003 Jan 17.

25.

Polypyrimidine tract-binding protein represses splicing of a fibroblast growth factor receptor-2 gene alternative exon through exon sequences.

Le Guiner C, Plet A, Galiana D, Gesnel MC, Del Gatto-Konczak F, Breathnach R.

J Biol Chem. 2001 Nov 23;276(47):43677-87. Epub 2001 Sep 13.

26.

TIA-1 and TIAR activate splicing of alternative exons with weak 5' splice sites followed by a U-rich stretch on their own pre-mRNAs.

Le Guiner C, Lejeune F, Galiana D, Kister L, Breathnach R, Stévenin J, Del Gatto-Konczak F.

J Biol Chem. 2001 Nov 2;276(44):40638-46. Epub 2001 Aug 20.

27.

Gene structure of the human receptor tyrosine kinase RON and mutation analysis in lung cancer samples.

Angeloni D, Danilkovitch-Miagkova A, Ivanov SV, Breathnach R, Johnson BE, Leonard EJ, Lerman MI.

Genes Chromosomes Cancer. 2000 Oct;29(2):147-56.

PMID:
10959094
28.

The RNA-binding protein TIA-1 is a novel mammalian splicing regulator acting through intron sequences adjacent to a 5' splice site.

Del Gatto-Konczak F, Bourgeois CF, Le Guiner C, Kister L, Gesnel MC, Stévenin J, Breathnach R.

Mol Cell Biol. 2000 Sep;20(17):6287-99.

29.

A processed pseudogene codes for a new antigen recognized by a CD8(+) T cell clone on melanoma.

Moreau-Aubry A, Le Guiner S, Labarrière N, Gesnel MC, Jotereau F, Breathnach R.

J Exp Med. 2000 May 1;191(9):1617-24.

30.

Characterization of two monoclonal antibodies against the RON tyrosine kinase receptor.

Montero-Julian FA, Dauny I, Flavetta S, Ronsin C, André F, Xerri L, Wang MH, Marvaldi J, Breathnach R, Brailly H.

Hybridoma. 1998 Dec;17(6):541-51.

PMID:
9890710
31.

hnRNP A1 recruited to an exon in vivo can function as an exon splicing silencer.

Del Gatto-Konczak F, Olive M, Gesnel MC, Breathnach R.

Mol Cell Biol. 1999 Jan;19(1):251-60.

32.

Multiple interdependent sequence elements control splicing of a fibroblast growth factor receptor 2 alternative exon.

Del Gatto F, Plet A, Gesnel MC, Fort C, Breathnach R.

Mol Cell Biol. 1997 Sep;17(9):5106-16.

33.

Macrophage stimulating protein (MSP) binds to its receptor via the MSP beta chain.

Wang MH, Julian FM, Breathnach R, Godowski PJ, Takehara T, Yoshikawa W, Hagiya M, Leonard EJ.

J Biol Chem. 1997 Jul 4;272(27):16999-7004.

34.

Identification of a gp100 epitope recognized by HLA-A3 restricted melanoma infiltrating lymphocytes.

Moreau-Aubry A, Fonteneau J, Labarriere N, Jotereau F, Houssaint E, Breathnach R.

Int J Oncol. 1997 Apr;10(4):841-6.

PMID:
21533454
35.

T cell response to Epstein-Barr virus transactivators in chronic rheumatoid arthritis.

Scotet E, David-Ameline J, Peyrat MA, Moreau-Aubry A, Pinczon D, Lim A, Even J, Semana G, Berthelot JM, Breathnach R, Bonneville M, Houssaint E.

J Exp Med. 1996 Nov 1;184(5):1791-800.

36.

The exon sequence TAGG can inhibit splicing.

Del Gatto F, Gesnel MC, Breathnach R.

Nucleic Acids Res. 1996 Jun 1;24(11):2017-21.

37.

Restricted expression of the ron gene encoding the macrophage stimulating protein receptor during mouse development.

Quantin B, Schuhbaur B, Gesnel MC, Doll'e P, Breathnach R.

Dev Dyn. 1995 Dec;204(4):383-90.

38.

Macrophage-stimulating protein activates Ras by both activation and translocation of SOS nucleotide exchange factor.

Li BQ, Wang MH, Kung HF, Ronsin C, Breathnach R, Leonard EJ, Kamata T.

Biochem Biophys Res Commun. 1995 Nov 2;216(1):110-8.

PMID:
7488076
40.

Structure of the promoter for the human macrophage stimulating protein receptor gene.

Del Gatto F, Gilbert E, Ronsin C, Breathnach R.

Biochim Biophys Acta. 1995 Jul 25;1263(1):93-5.

PMID:
7632741
41.

A Crouzon syndrome synonymous mutation activates a 5' splice site within the IIIc exon of the FGFR2 gene.

Del Gatto F, Breathnach R.

Genomics. 1995 Jun 10;27(3):558-9. No abstract available.

PMID:
7558045
43.

Identification of the ron gene product as the receptor for the human macrophage stimulating protein.

Wang MH, Ronsin C, Gesnel MC, Coupey L, Skeel A, Leonard EJ, Breathnach R.

Science. 1994 Oct 7;266(5182):117-9.

PMID:
7939629
44.
45.

Control of BEK and K-SAM splice sites in alternative splicing of the fibroblast growth factor receptor 2 pre-mRNA.

Gilbert E, Del Gatto F, Champion-Arnaud P, Gesnel MC, Breathnach R.

Mol Cell Biol. 1993 Sep;13(9):5461-8.

46.

A novel putative receptor protein tyrosine kinase of the met family.

Ronsin C, Muscatelli F, Mattei MG, Breathnach R.

Oncogene. 1993 May;8(5):1195-202.

PMID:
8386824
47.
48.

Human interleukin-2-IgM heavy-chain-fusion proteins are cytotoxic for cells expressing the IL2 receptor.

Vie H, Gauthier T, Breathnach R, Bonneville M, Godard A, Dietrich J, Karam G, Gesnel MC, Peyrat MA, Jacques Y, et al.

Transplant Proc. 1993 Feb;25(1 Pt 1):741-2. No abstract available.

PMID:
8438463
49.

Recognition of shared melanoma antigen by HLA-A2-restricted cytolytic T cell clones derived from human tumor-infiltrating lymphocytes.

Viret C, Davodeau F, Guilloux Y, Bignon JD, Semana G, Breathnach R, Jotereau F.

Eur J Immunol. 1993 Jan;23(1):141-6.

PMID:
8419164
50.

Human fusion proteins between interleukin 2 and IgM heavy chain are cytotoxic for cells expressing the interleukin 2 receptor.

Vié H, Gauthier T, Breathnach R, Bonneville M, Godard A, Dietrich J, Karam G, Gesnel MC, Peyrat MA, Jacques Y, Soulillou JP.

Proc Natl Acad Sci U S A. 1992 Dec 1;89(23):11337-41.

Supplemental Content

Loading ...
Support Center